首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Adjuvant Therapy of Oral Chinese Herbal Medicine for Menopausal Depression: A Systematic Review and Meta-Analysis
【24h】

Adjuvant Therapy of Oral Chinese Herbal Medicine for Menopausal Depression: A Systematic Review and Meta-Analysis

机译:女性中药治疗前瞻性抑郁症的辅助治疗:系统审查和荟萃分析

获取原文
           

摘要

Objective. The aim of this meta-analysis was to evaluate the effectiveness of oral Chinese herbal medicine (OCHM) combined with pharmacotherapy for menopausal depression. Methods. The electronic databases were searched from their inception to December 25, 2016, comprising PubMed, Embase, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure (CNKI), Wanfang database, and Chinese Biomedical (CBM) database. Randomized controlled trials investigating the effectiveness of OCHM combined with pharmacotherapy for the people with menopausal depression were eligible. Risk of bias was evaluated according to the Cochrane handbook. Meta-analyses were performed to pool the effect size. Heterogeneity and publication bias were also examined. Results. Twenty-two RCTs with 1770 participants were included in the review. None of the studies used placebo as the control and the risk of bias was high in blinding the participants and personnel. Overall, the meta-analysis demonstrated that adjuvant therapy of OCHM was effective in reducing the Hamilton Rating Scale for Depression (HAMD) scores compared to pharmacotherapy (MD = −3.75; 95% CI = −5.22, −2.29; P < 0.00001). The meta-analysis also suggested that OCHM adjuvant therapy for menopausal depression was superior to pharmacotherapy in terms of response rate of reducing HAMD scores (RR = 1.17; 95% CI = 1.10, 1.25; I2 = 55%). Conclusions. OCHM may provide additional effectiveness to pharmacotherapy for the people with menopausal depression. RCTs including the placebo control were required to further determine the additional efficacy of OCHM for menopausal depression.
机译:客观的。该荟萃分析的目的是评估口腔中药(OCHM)的有效性与绝经抑郁症的药物治疗联合。方法。从2016年12月25日的成立中搜索了电子数据库,包括受控试验,中国国家知识基础设施(CNKI),万芳数据库和中国生物医学(CBM)数据库的PubMed,Embase,Cochrane中央登记册。随机对照试验研究OCHM与预期抑郁症的药物治疗合并的药物治疗有资格。根据Cochrane手册评估偏差风险。进行Meta分析以汇集效果大小。还检查了异质性和出版物偏见。结果。审查中包含二十二个rct有1770名参与者的RCT。没有一项研究使用安慰剂作为控制和偏见的风险在使参与者和人员蒙蔽中很高。总体而言,荟萃分析表明,与药物疗法相比,OCHM的佐剂治疗可有效地减少抑郁症(HAMD)评分(MD = -3.75; 95%CI = -5.22,-2.29; p <0.00001)。 Meta分析还表明,在减少HAMD评分的反应速率方面,ochm佐剂治疗优于药物疗法(RR = 1.17; 95%CI = 1.10,1.25; I2 = 55%)。结论。 Ochm可以为具有更年期抑郁症的人的药物提供额外的效果。需要包括安慰剂对照的RCT,以进一步确定Ochm对更长期抑郁症的额外疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号